Stock Price Quote

JUBILANT PHARMOVA LTD.

NSE : JUBLPHARMABSE : 530019ISIN CODE : INE700A01033Industry : Pharmaceuticals & DrugsHouse : Jubilant Bhartia
BSE1059.800.5 (+0.05 %)
PREV CLOSE ( ) 1059.30
OPEN PRICE ( ) 1045.25
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 6611
TODAY'S LOW / HIGH ( )1045.25 1079.90
52 WK LOW / HIGH ( )823.7 1250
NSE1060.80-0.5 (-0.05 %)
PREV CLOSE( ) 1061.30
OPEN PRICE ( ) 1051.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 150305
TODAY'S LOW / HIGH( ) 1048.60 1080.50
52 WK LOW / HIGH ( )802 1248
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 21-06 1978
Management Info
Shyam S Bhartia - Chairman Priyavrat Bhartia - Managing Director
Registered Office

Address Bhartiagram ,Jyotiba Phoolay Nagar, ,
Gajraula,
Uttar Pradesh-244223

Phone 05924-267437

Email invstors@jubl.com

Website www.jubilantpharmova.com

Registrars Details
Alankit Assignments Ltd.
205-208 , Anarkali Complex,Jhandewala Extension,,New Delhi
Listing : BSE, NSE

NEWS

02Dec Jubilant Pharmova informs about appoi
Jubilant Pharmova has informed about the appointment of Daniel J. O’Conn..
05Nov Jubilant Pharmova’s arm gets 9 observa
U.S. Food and Drug Administration (USFDA) has concluded audit at Jubilan..
31Oct Jubilant Pharmova informs about outcom
Pursuant to the provisions of Regulation 33 read with Regulation 30 and..
10Oct Jubilant Pharmova informs about press
Pursuant to Regulation 30 of the Securities and Exchange Board of India..
10Oct Jubilant Pharmova’s arm launches New S
Jubilant Pharmova’s wholly owned subsidiary -- Jubilant HollisterStier L..

Financials

in Millions
QTR Sep 25 ANNUAL 25
Net Profit-64192
Gross Profit 85 376
Operating Profit 1261317
Net Sales 6647457

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Procter&Gamble Healt (BSE)
peergroup  5694.85 (1.04%)
M.Cap ( in Cr)9453.10
Haleos Labs (BSE)
peergroup  1385.00 (3.40%)
M.Cap ( in Cr)418.73
Pfizer (BSE)
peergroup  5027.50 (0.90%)
M.Cap ( in Cr)22999.67
Venus Remedies (BSE)
peergroup  786.50 (5.00%)
M.Cap ( in Cr)1051.31
Ajanta Pharma (BSE)
peergroup  2655.30 (1.37%)
M.Cap ( in Cr)33174.16

Shareholding Pattern

MUTUAL FUNDS/UTI 7.13%
PROMOTERS 47.68%
NON-INSTITUTION 25.24%
FI/BANKS/INSURANCE 1.13%
GOVERNMENT 0%
FII 0%

About Jubilant Pharmova Ltd.

Jubilant Pharmova Ltd. was incorporated in the year 1978. Its today's share price is 1059.8. Its current market capitalisation stands at Rs 16880.62 Cr. In the latest quarter, company has reported Gross Sales of Rs. 7457 Cr and Total Income of Rs.8453 Cr. The company's management includes Shivpriya Nanda, Harsh Mahajan, Shirish G Belapure, Arun Seth, Vivek Mehra, Sushil Kumar Roongta, Arjun Shanker Bhartia, Priyavrat Bhartia, Hari S Bhartia, Shyam S Bhartia, Naresh Kapoor.

It is listed on the BSE with a BSE Code of 530019 , NSE with an NSE Symbol of JUBLPHARMA and ISIN of INE700A01033. It's Registered office is at Bhartiagram ,Jyotiba Phoolay Nagar, Gajraula-244223, Uttar Pradesh. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are BSR & Co LLP, KN Gutgutia & Co, Walker Chandiok & Co LLP

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.